Best-in-class splicing signal in DM1, a disease with no approved therapy, contingent on whether dose-escalation data translates to clinical function

PepGen is a clinical-stage biotechnology company developing an antisense therapy for myotonic dystrophy type 1, a muscle disease that currently has no approved treatment, though the company's lead therapy is not yet approved.

PepGen's peptide-conjugated antisense approach showed dose-proportional splicing correction in Phase 1, reaching 53.7% at 15 mg/kg, the strongest signal reported in myotonic dystrophy type 1, a multisystem muscle disease with no approved treatment. The thesis resolves on whether the 10 mg/kg and 12.5 mg/kg Phase 2 cohorts deliver functional improvement on the vHOT endpoint sufficient to anchor a registrational program. A partial clinical hold tied to preclinical pharmacology questions, now cleared for dose escalation by the DSMB, remains an unresolved regulatory overhang that could delay or reshape the filing path.